GlassScriptPhysician profile
Precious Sarver
NPI 1972238467
$2,719.06
in general payments reported to CMS, 2019-2025
12 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $388 · 2023: $827 · 2024: $1,007 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.08 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $775.33 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $549.14 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $371.18 | 2024-2025 | |
| Alkermes, INC. | $326.07 | 2022-2023 | Vivitrol |
| Janssen Pharmaceuticals, INC | $232.34 | 2023 | Spravato |
| Axsome Therapeutics, INC. | $178.71 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $120.84 | 2022 | |
| Lundbeck LLC | $74.69 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $34.13 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bausch Health US, LLC | $20.90 | 2023 | Wellbutrin, Aplenzin |
| Bayer Healthcare Pharmaceuticals INC. | $20.13 | 2022 | |
| Lilly USA, LLC | $15.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Precious Sarver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.